Free Trial
NASDAQ:OBSV

ObsEva (OBSV) Stock Price, News & Analysis

ObsEva logo

About ObsEva Stock (NASDAQ:OBSV)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
1,360 shs
Average Volume
8.94 million shs
Market Capitalization
$7.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Receive OBSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ObsEva and its competitors with MarketBeat's FREE daily newsletter.

OBSV Stock News Headlines

ObsEva Announces Update on Board of Directors
Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
ObsEva SA OBSN
ObsEva SA OBSEF
ObsEva (NASDAQ: OBSV)
See More Headlines

OBSV Stock Analysis - Frequently Asked Questions

ObsEva SA (NASDAQ:OBSV) posted its earnings results on Thursday, November, 4th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.23.

ObsEva (OBSV) raised $98 million in an initial public offering on Thursday, January 26th 2017. The company issued 6,500,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.

Shares of OBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ObsEva investors own include NIO (NIO), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Allena Pharmaceuticals (ALNA), Bionano Genomics (BNGO) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
11/04/2021
Today
5/15/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OBSV
Fax
N/A
Employees
50
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-58,380,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$20.11 million
Price / Cash Flow
N/A
Book Value
$0.41 per share
Price / Book
N/A

Miscellaneous

Free Float
66,743,000
Market Cap
$7.94 million
Optionable
Not Optionable
Beta
0.68

Social Links

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:OBSV) was last updated on 5/16/2025 by MarketBeat.com Staff
From Our Partners